TY - JOUR
T1 - Trials for neurodegenerative diseases
T2 - time to innovate
AU - Mehta, Arpan R
AU - Chataway, Jeremy
AU - Pal, Suvankar
AU - Parmar, Mahesh K B
AU - Chandran, Siddharthan
PY - 2021/12
Y1 - 2021/12
N2 - The remarkable progress in our understanding of the mechanisms underlying neurodegenerative diseases heralds an era when neurologists would be at the vanguard of regenerative medicine, instead of chroniclers of decline. To capitalise on these advances that are identifying ever more therapeutic candidates, whether repurposed or entirely new, there is an urgent need for refined methods to test these putative medicines in clinical trials. Our field has the opportunity to learn from innovations in trial design, particularly those pioneered in oncology.
AB - The remarkable progress in our understanding of the mechanisms underlying neurodegenerative diseases heralds an era when neurologists would be at the vanguard of regenerative medicine, instead of chroniclers of decline. To capitalise on these advances that are identifying ever more therapeutic candidates, whether repurposed or entirely new, there is an urgent need for refined methods to test these putative medicines in clinical trials. Our field has the opportunity to learn from innovations in trial design, particularly those pioneered in oncology.
UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85119273910&origin=inward
U2 - 10.1016/S1474-4422(21)00388-4
DO - 10.1016/S1474-4422(21)00388-4
M3 - Article
C2 - 34800413
SN - 1474-4422
VL - 20
SP - 984
JO - Lancet Neurology
JF - Lancet Neurology
IS - 12
ER -